购物车
- 全部删除
- 您的购物车当前为空
Codrituzumab (GC3)是一种人源化针对 glypican-3 肝癌蛋白的抗体,可与索拉非尼联合使用来研究不可治愈的晚期肝细胞癌 (HCC) 。
为众多的药物研发团队赋能,
让新药发现更简单!
Codrituzumab (GC3)是一种人源化针对 glypican-3 肝癌蛋白的抗体,可与索拉非尼联合使用来研究不可治愈的晚期肝细胞癌 (HCC) 。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,230 | 现货 | |
2 mg | ¥ 1,850 | 现货 | |
5 mg | ¥ 3,150 | 现货 | |
10 mg | ¥ 4,520 | 现货 | |
25 mg | ¥ 6,990 | 现货 | |
50 mg | ¥ 9,420 | 现货 | |
100 mg | ¥ 12,700 | 现货 |
产品描述 | Codrituzumab (GC3) is a humanized antibody against the glypican-3 hepatocellular carcinoma protein that can be used in combination with sorafenib to study incurable advanced hepatocellular carcinoma (HCC). |
别名 | 考曲妥珠单抗, RO5137382, RG-7686, GC33 |
分子量 | 145.58 kDa |
CAS No. | 1365267-33-9 |
存储 | store at low temperature | store at -80°C | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.